Raymond James Financial Services Advisors’s Amplify Treatments, Testing and Advancements ETF GERM Stock Holding History

Raymond James Financial Services Advisors’s Portfolio GERM Stock Details GERM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-21,572	Closed	-$769K	–	3503
2021 Q4	$769K	Buy	+21,572	New	+$809K	﹤0.01%	2127

Other funds holding GERM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

GBWM

Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

IWM

IHT Wealth Management Chicago, Illinois $4.3B AUM 21.02% 1-Year Est. Return

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Raymond James Financial Services Advisors's GERM Position: Q1 2022 in Review

Raymond James Financial Services Advisors sold out of Amplify Treatments, Testing and Advancements ETF (GERM) in Q1 2022, closing a stake of 21,572 shares — an estimated $769K sold.

Raymond James Financial Services Advisors first reported a position in GERM in Q4 2021 and held it in 1 quarter. The position peaked at $769K in Q4 2021. 28 funds tracked by Wall St. Rank hold GERM as of Q1 2022.

Raymond James Financial Services Advisors reported no remaining Amplify Treatments, Testing and Advancements ETF position as of Q1 2022 after selling out during the quarter.
Raymond James Financial Services Advisors sold 21,572 Amplify Treatments, Testing and Advancements ETF shares in Q1 2022, an estimated $769K.
Raymond James Financial Services Advisors first reported a position in Amplify Treatments, Testing and Advancements ETF in Q4 2021 and held it in 1 quarter.
Raymond James Financial Services Advisors's Amplify Treatments, Testing and Advancements ETF position peaked at $769K in Q4 2021.
28 funds tracked by Wall St. Rank held Amplify Treatments, Testing and Advancements ETF as of Q1 2022.

Based on Raymond James Financial Services Advisors's 13F filing for Q1 2022, filed 11 May 2022.